

UPPER EXTREMITY SPASTICITY Recommendations i. Spasticity and contractures may be prevented or treated by antispastic pattern positioning, range-of-motion exercises, and/or stretching (Evidence Levels: Early-Level C, Late-Level C). a. Routine use of splints is not recommended in the literature (Evidence Levels: Early-Level A, C Late-Level B); however, optimal protocols for utilizing splinting for improvement or preservation of tissue length and spasticity management have not yet been determined. b. In some select patients, the use of splints may be useful and should be considered on an individualized basis (Evidence Level C). A plan for monitoring the splint for effectiveness should be provided (Evidence Level C). ii. Chemodenervation using boutinum toxin can be used to increase range of motion and decrease pain for patients with focal and/or symptomatically distressing spatiety (Evidence Levels: Early-Level C; Late-Level A). Oral medications can be prescribed for the treatment of disabling spasticity: Tizanidine can be used to treat more generalized, disabling spasticity. (Evidence Levels: Early-Level C; Late-Level B). **UPPER EXTREMITY** CONTINUED b. Baelofen can be used as a lower cost alternative but has not been studied in this population (Esidence Lewels: Early-Level C; Late-Level C). Note: Baelofen initial dusing should be low and titrated upwards showly as tolerated by patients. - Benzediazepines should be avoided due to sedating side effects, which may impair recovery (Evidence Level: Early-Level C; Late-Level C). iv. The presence of spasticity should not limit the use of strength training in the arm (Evidence Level: Early-Level C). Management of Hemiplegic Shoulder Pain i. Treatment of hemiplegic shoulder pain related to limitations in range of motion includes gentle stretching and mobilization techniques, and typically involves increasing external rotation and abduction. (Evidence Level B). a. Active range of motion should be increased gradually in conjunction with restoring alignment and strengthening weak muscles in the shoulder gridle (Evidence Level B). ii. If there are no contraindications, analgesics (such pain relief (Evidence Level C). iii. Injections of botulinum toxin into the subscapularis and pectoralis muscles could be used to treat hemiplegic shoulder pain thought to be related to spassificity (Evidence Level B). iv. Subacromial corticosteroid injections can be used in patients when pain is thought to be related to injury or inflammation of the subacromial region (rotator cuff or bursa) in the hemiplegic shoulder (Evidence level B). **SPASTICITY** AND PAIN

Recommendations i. Antispastic pattern positioning, range-of-motion exercises and/or stretching may be considered for prevention or treatment of spasticity and contractures (Evidence Level: Early-Level C; Late-Level B). ii. Ankle splints used at night and during assisted standing may be considered for prevention of ankle contracture in the hemiparetic lower extremity (Evidence Level C).

iii. Chemodenervation using botulinum toxin can be used to reduce sparticity, increase range of motion, and improve gail, for patients with focal and/or symptomatically distressing spasticity (Evidence Level: Early-Level C; Latts-Level A).

iv. Oral medications can be prescribed for the treatment of disabiling spasticity:
i. Tizanidine can be used to treat more generalized, disabiling spasticity. (Evidence Levels: Early-Level C; Latts-Level B).
iii. Baclofien can be used as a lower cost alternative to treat more generalized disabiling spasticity (Evidence Levels: Early-Level C; Latts-Level B).
iii. Baclofien can be used as a lower cost alternative to treat more generalized disabiling spasticity (Evidence Levels: Early-Level C; Latts-Level C).
iiii. Benzodiazepines should be avoided due to sedating side effects, which may impart recovery (Evidence Level: Early-Level C; Latts-Level C).

iii. Statistical Seal of the control of the control of strength training in the leg (Evidence Level: Early-Level C, Latts-Level C).
iii. Intrathecal Baclofen should be considered for specific cases of severe, intratable and disabiling/ painful spasticity (Evidence Level: Latts-Level B)



Level	Research Design	Description
Level 1a	Randomized Controlled Trial (RCT)	More than 1 Higher RCT: Randomized Controlled Trial, PEDro score ≥ 6. Includes within subjects comparison with randomized conditions and cross- over designs.
Level 1b	RCT	1 Higher Randomized Controlled Trial, PEDro score ≥ 6.
Level 2	RCT	Lower RCT, PEDro score < 6
	Prospective Controlled Trial (PCT)	Prospective Controlled Trial (not randomized).
	Cohort	Prospective Longitudinal study using at least 2 simila groups with one exposed to a particular condition.
Level 3	Case Control	A retrospective study comparing conditions, including historical cohorts.
Level 4	Pre-Post	A prospective trial with a baseline measure, intervention, and a post-test using a single group of subjects.
	Post-test	A prospective post-test with two or more groups (intervention followed by post-test and no re-test or baseline measurement) using a single group of subjects.
	Case Series	A retrospective study usually collecting variables from a chart review.




	STRETCHING
Con	clusions Regarding Stretching Programs to Prevent Contracture Formation
	ere is level 1b evidence that a nurse-led stretching program may improve range of motion in the per stremity and reduce pain in the chronic stage of stroke.
Th	ere is level 1b evidence that a hand stretching device may improve spasticity in the upper limb.
im	ere is level 2 evidence that supplementing stretching programs with joint stabilization exercises m prove muscle thickness in the affected arm as well as arm function; however, no such effect is foun hen the stretching programs are delivered alone.
	urther research is needed to determine a stretching program that may improve upper limi pasticity.
1000	

SPLINTING Conclusions Regarding the Use of Splints to Prevent Ankle Contracture There is level 1b evidence that both a tilt table and night splint may prevent ankle contracture in the early period following stroke. Splints and tilt tables are both effective in the prevention of ankle contracture. Conclusions Regarding Splinting There is level 1a and level 2 evidence that splinting does not reduce the development of contracture nor reduce spasticity in the upper extremity; however, it may improve passive range of motion. Hand splints alone do not reduce spasticity or prevent contracture.



PHYSICAL THERAPY Conclusions Regarding Physical Therapy to Reduce Sparticity There is level 15 evidence that rehabilitation programs compared to standard medications may improve sparticity for the elbows, fingers and plantar flexion. There is level 1a evidence that ankle exercises compared to conventional therapy may not improve gait, ankle range of motion or sparticity but may improve be balance. There is level 3 evidence that robotic training may not improve sparticity, gait, or sparticity. There is level 1b evidence that a single session of isokinetic or isotonic muscle stretch may not improve measures of gait. Evidence is inconclusive for the effect of rehabilitation programs, andle exercises, robotic training and other physical therapes on sparticity port-etroke. Conclusions Regarding Physical Therapy There is level 1a and limited level 2 evidence that physical therapy may not improve motor function or contracture. Physical therapy may not decrease spasticity, or pain, or contracture, or improve upper extremity motor function.



botulinum toxin.	nd may be an attractive treatment	t option for stroke patients compared to mmarized in Table 10.5.8.1.
Table 10.5.8.1 Summar Author, Year Study Design (PEDro Score) Sample Size	y of RCT(s) Evaluating Shockwave Ti	Main Outcome(s) Result
Sanatamato et al. (2013) Italy RCT (8) N=16	E: Botox + extracorporeal shockwave therapy C: Botox + electrical stimulation therapy	Modified Ashworth Scale (MAS) (+) Spasm Frequency Scale (+) Visual Analogue Scale (+)
16		- Toda Manager Cont (1)